Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tovorafenib and Rituximab in Classical Hairy Cell Leukemia
NCT06965114Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2026
- Primary completion
- Mar 2030
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tovorafenib in hairy cell leukemia (HCL) (3 arms), sponsored by National Cancer Institute. Primary endpoints: Incidence of adverse events and Minimal residual disease negative complete remission rate. Started May 2026; status: recruiting.
02
Drugs
tovorafenib
03
Conditions
hairy cell leukemia (HCL)
Beyond the preview
Go deeper on NCT06965114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06965114.